Navigation Links
Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets

Data Presented at Society for Biomolecular Sciences Conference

THE WOODLANDS, Texas, April 18, 2007 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated announced that data was presented today highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular Sciences 13th Annual Conference & Exhibition in Montreal, Canada. These target discoveries were made in a collaboration between Lexicon and Genentech that was initiated in December 2002 and expanded in November 2005 to advance the research, development and commercialization of new biologic drugs. Lexicon has developed antibodies for one of these targets, designated LG842, which it is now advancing through preclinical research.

Data presented today revealed that the deletion or neutralization of LG842, a circulating protein expressed predominantly in adipose tissue, placenta, pancreas and liver, resulted in lower triglycerides and cholesterol in in vivo models.

"Our in vivo studies, recently corroborated by human genetic data, have defined an important new pathway for potential treatments of dyslipidemia and metabolic disorders related to cardiovascular disease," commented Brian P. Zambrowicz, Ph.D., Lexicon's chief scientific officer. "We believe that our collaboration with Genentech has been enormously fruitful. We have been able to elucidate the function of a number of genes that have shown promise in important areas of medicine."

In preclinical studies, treatment with Lexicon's LG842 antibodies was shown to decrease plasma triglycerides and cholesterol. Lexicon has the option to choose six targets from the collaboration to advance into biotherapeutics drug discovery efforts. LG842 was one of the first two targets selected by Lexicon for internal development.

Gene Knockout Technology

Lexicon's proprietary technology allows scientists to create in vivo mode
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
2. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
3. Vaxiion Researchers Discover Novel Vaccine Delivery System in Collaboration with San Diego State University
4. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
5. Study of Drug Therapy for Compulsive Buying Yields a Puzzle, Stanford Researcher Says
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. New Information on the Potential of Plasmin Shared at ISTH Congress
8. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
9. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
(Date:2/26/2015)... -- Finesse expands office in Leicester, United Kingdom ... of its operations in Leicester , ... for customers is expected shortly afterward. With ... the current office, the new premises will double the ... Finesse to bring on more service personnel. The new ...
(Date:2/26/2015)... , Feb. 26, 2015  AbbVie (NYSE: ... of studies in its neuroscience and oncology development ... 67 th American Academy of Neurology annual ... from April 18-25. The accepted abstracts feature results ... addition to investigational treatments in AbbVie,s pipeline. Presentations ...
(Date:2/26/2015)... , Feb. 26, 2015  Mobility Ventures LLC, an ... with Bank of America (NYSE: BAC ) ... receive financing of the revolutionary MV-1 - - the ... the ground up to provide safe and comfortable transportation ... use their loan to purchase a new MV-1 vehicle ...
Breaking Medicine Technology:New Finesse Office in United Kingdom 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... Actavis has received approval from the U.S. Food ... treatment of attention deficit/hyperactivity disorder (ADHD). Actavis ... 25 mg, 40 mg, 60 mg, 80 mg and 100 ... to Eli Lilly and Company,s Strattera®, has been set. The ...
... Services of America, Inc. (ROSA), a subsidiary of Ambulatory ... has entered into an agreement with the Department of ... School of Medicine to embark on a Cooperative Quality ... of Radiation Oncology will review quality assurance activities in ...
Cached Medicine Technology:Actavis Receives FDA Approval of Atomoxetine HCl Capsules 2Radiation Oncology Services of America, Inc. to Work With Washington University on Quality Assurance Initiative 2
(Date:3/1/2015)... CrossFit Attollo is a CrossFit gym located in Vancouver ... to new members. Now through the end of March ... will receive their fourth month half off. , ... The three month contract is only $264, dropping the price ... comes in at only $55. The special saves new members ...
(Date:2/28/2015)... February 28, 2015 In recent years Medical ... of practicing physicians as a way for them to expand ... regarding Cannabis as medicine. Since the FDA still lists Cannabis ... resources available to licensed physicians that can help guide ... Dr. Deborah Malka in Santa Cruz, CA is a ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 In ... Duncan Fletcher of Game Change Athlete ... Shannon Leinert about the benefits of athlete development and ... some of the unique challenges that athletes face and ... and future success. , Fletcher became involved in athlete ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... Portland, Oregon (PRWEB) February 28, 2015 ... Portland, Oregon, is offering a new special. Throughout ... denture relines. , This service ... from sleep problems and pain. Patients may notice certain ... and need relining. These symptoms include: , 1.    Pain, ...
Breaking Medicine News(10 mins):Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2
... have found a new family of therapeutic agents that ... growth of breast cancer cells. The results of the ... The Endocrine Society,s 90th Annual Meeting in San Francisco. ... therapeutic called TPBM and related compounds are likely to ...
... have discovered a new family of agents that inhibit ... described today at a meeting of the Endocrine Society, ... to combat estrogen-dependent breast cancers. , "This cell-based study ... to be effective in tumors that remain dependent on ...
... treatments, researchers say , , MONDAY, June 16 (HealthDay News) ... that might one day be added to the armamentarium ... "This is a potential new approach to treating hormonally ... officer of the American Cancer Society. "If it proves ...
... 16 The National Center for Healthcare,Leadership (NCHL) ... MD, chief,executive officer of Denver Health, as the ... her significant and lasting contributions,to healthcare. Under her ... system that achieves organizational,excellence while treating at-risk populations, ...
... S.C., June 16 The planned,Presbyterian College school of ... the dean of the school of pharmacy and assistant,provost ... Charleston,W. Va. has accepted the college,s offer to become ... developing the first school of pharmacy in,Upstate South Carolina., ...
... of RU-486,s companion drug misoprostol is safe, but vaginal use ... a drug given with RU-486 to terminate a pregnancy may ... in women taking the drugs since 2000, a study by ... is FDA-approved to be taken by mouth along with RU-486 ...
Cached Medicine News:Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:Team discovers new inhibitors of estrogen-dependent breast cancer cells 2Health News:New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 3Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 4Health News:Presbyterian College Announces First Dean of New Pharmacy School 2Health News:Presbyterian College Announces First Dean of New Pharmacy School 3Health News:Abortion drug's off-label use may have led to deaths 2Health News:Abortion drug's off-label use may have led to deaths 3
Inquire...
... Pipette Tracker is an automated solution for ... and performance testing for all pipettes and ... from any balance Supports all ... 8655, DIN 12650, ISO 9000, NCCLS and ...
... V-shaped bottom allows easy withdrawal of solution ... bag ,• Corner pouring lips facilitate ... designed for 4, 8, and 12 channel ... withdrawal of practically all of the solution. ...
... V-shaped bottom allows easy withdrawal of solution ... bag, ,• Corner pouring lips facilitate ... designed for 4, 8, and 12 channel ... permits withdrawal of practically all of the ...
Medicine Products: